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The research on potential biomarker discovery for drug-induced phospholipidosis 
revealed novel plasma and urine biomarkers to monitor phospholipidosis status in 
noninvasive way. Utilization of these biomarkers can avoid drug-induced 
phospholipidosis and it is critically beneficial to improve quality of life for patients who 
suffer from drug-induced toxicity. In this thesis, I investigated metabolomics research to 
identify phenylacetylglycine (PAG) to hippuric acid (HA) ratio in plasma as potential 
indicator to monitor phospholipidosis in rats and established a highly sensitive and 
reliable assay method. 
In chapter 1, I investigated biomarker discovery in rat urine after phospholipidosis 
inducing drugs administration. Metabolomics study revealed PAG to HA ratio in urine 
was increased in time and dose dependent manners and it was well correlated with 
histopathological observation. These urine biomarkers were applied to plasma since the 
dynamics of these metabolites in urine were expected to linked with their plasma 
concentrations. The HA and PAG concentrations and PAG to HA ratios were monitored 
before and after treatment with amiodarone, a well-known phospholipidosis inducing 
drug. The PAG to HA ratio showed clear dose and time dependent increases after 
amiodarone administration. And the increment of the PAG/HA ratio decreased in a time 
dependent manner after the dosing period and this was consistent with the results from 
the histopathological evaluation. 
To confirm the utility of their potential biomarkers, a reliable and robust analytical 
method development is important. In chapter 2, I developed and validated a 
quantification method by using liquid chromatography-tandem mass spectrometry 
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(LC/MS/MS) for simultaneous quantification of HA and PAG in rat urine. The 
established analytical method showed good precisions and accuracies confirmed by the 
assessments for intra- and inter-day assay validation procedures. 
In summary, these novel, non-invasive and highly quantitative biomarkers to monitor 
drug-induced phospholipidosis status is critically beneficial to avoid drug derived 
serious toxicity to improve the quality of life for patients. 
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CAD   Cationic amphiphilic drug  
DIPL  Drug induced phospholipidosis 
HA   Hippuric acid 
LC/MS/MS  liquid chromatography-tandem mass spectrometry 
NMR  Nuclear magnetic resonance 
PAG   Phenylacetylglycine 
PLD   Phospholipidosis 
SRM   Selected reaction monitoring 
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Drug induced phospholipidosis (DIPL) is a lysosomal storage disorder characterized 
by an abnormal accumulation of phospholipids in cells such as hepatocytes, 
lymphocytes and macrophages and tissues (Anderson and Borlak, 2006; Reasor and 
Kacew, 2001; Tengstrand et al., 2010). In these cells, myeloid bodies can be observed 
using transmission electron microscopy (TEM) (Josepovitz et al., 1985; Mortuza et al., 
2003). Myeloid bodies occur naturally in the late endosomes/lysosomes of tissues where 
they act as storage vesicles for secreted and undigested lipids and proteins (Schmitz and 
Müller, 1991). Excess undigested components in lysosome leads the accumulation of 
myeloid bodies and other inclusions in the cells in DIPL (Mohammad and Haoxing, 
2014). Currently more than 50 drug candidates and marketed drugs including 
anti-depressants, antianginal, antimalarial, and cholesterol-lowering agents have been 
reported to cause DIPL  and most of them that cause DIPL are cationic amphiphilic 
drugs (CADs) (Lüllmann et al., 1978, Halliwell, 1997, Reasor, 1989). Amiodarone, an 
antiarrhythmic drug with CAD structure used to treat and prevent irregular heartbeats, 
is well-known to induce phospholipidosis. Amiodarone has numerous side effects to 
various tissues including lung, thyroid, eye, liver and skin, especially it causes fatal 
severe pulmonary fibrosis toxicities (Baumann et al., 2017). While it's quite important 
to monitor the state of phospholipidosis, TEM method has limited utility to monitor in 
humans because of the invasive nature of acquiring patient tissue biopsy samples. A 
qualified biomarker of DIPL in the blood, plasma or urine is needed to provide a more 
routine, non-invasive, and cost effective means to monitor DIPL in the clinic. 
There are approximately 50 congenital lysosomal metabolic disorders like Gaucher 
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disease, Fabry disease and Niemann-Pick disease (Grabowski, 2012, Kaminsky and 
Lidove, 2014). These diseases are caused by lysosomal dysfunction as a consequence of 
deficiency of lysosomal enzymes required for the sphingolipids metabolism to 
accumulate glycolipids or phospholipids like glucosylceramide, galactocerebroside and 
sphongomyeline (Segatori, 2014). And the histopathological findings also observe 
myeloid bodies in the cells of these diseases (Mahmud, 2014, Liu et al., 2014). In that 
sense there are several similarity points between DIPL and lysosomal disorders. On the 
other hand, the cause of a majority of lysosomal disorders are clearly identified as single 
genetic mutation of specific lipid metabolism, whereas the mechanism of DIPL has not 
been extensively studied and is not well understood yet (Hostetler and Matsuzawa, 
1981; Joshi et al., 1988; Reasor and Kacew, 2001; Xia et al., 2000). Additionally, unlike 
lysosomal disorders, there are various species of lipids accumulated in DIPL. From 
these factors, the possible mechanism of DIPL should be participated not only 
phospholipids metabolism but also biosynthesis of the phospholipids and other 
homeostasis of the lipid components.  
Metabolomics is the comprehensive analytical research for small molecules, such as 
sugar, amino acid and lipid components to explore the biological signatures of living 
systems to pathophysiological stimuli or genetic modification (Wei, 2011). Among 
so-called "omics" approach including genomics, transcriptomics and proteomics, 
metabolomics is to examine the final downstream product of the central dogma and is 
closest to the functional phenotype of the cell or organism. The metabolome is thus also 
closer and more susceptible to external perturbations such as drug treatment. 
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Furthermore, well established metabolic pathway map with around 4000 estimated 
small molecules can lead the mechanism hypothesis easily compared with that by the 
millions or tens of thousands of proteins, transcripts and genes (Leader et al., 2011). 
The other advantage of metabolomics approach is their concentrations, unlike other 
"omics" measures, directly reflect the underlying biochemical activity and state of cells 
and/or tissues. However, in terms of constructing an absolute quantification of 
endogenous metabolite remains as technical issues since coexisting substances interfere 
with metabolite in biological samples to hamper sensitivity and selectivity (Annesley 
2003, Mallet et al., 2004). Thus, highly accurate and robust metabolite assay method 
development and validation is quite important for testing the hypothesis of biological 
alteration by external stimulations. 
In this thesis, I investigated biomarker discovery by metabolomics approach using 
nuclear magnetic resonance (NMR) in rat urine after administration of phospholipidosis 
inducing drugs of amiodarone, chloroquine, quinacrine, tamoxifen and fluoxetine. The 
metabolomics analysis revealed that hippuric acid (HA) and phenylacetylglycine (PAG) 
levels were well correlated with histopathologic changes in DIPL in rats, such as foamy 
macrophage accumulation and vacuolated lymphocyte numbers. Simultaneous 
quantification methods for HA and PAG in rat urine was successfully developed and 
validated using liquid chromatography-tandem mass spectrometry (LC/MS/MS). By 
using the established analytical method I confirmed the PAG/HA ratio showed clear 
dose and time dependent increases after amiorarone administration and it decreased 
after dosing period that also reflect the histopathologic findings. Since phenylalanine, 
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an essential amino acid for animals including human, is known to be a precursor for 
both HA and PAG, its two major metabolic alterations, such as inhibition of 
beta-oxidation at phenylalanine to HA pathway by PLD-inducing drugs and 
concomitant acceleration of a compensation pathway to PAG, may be considered to be 
underlying mechanism for the change in PAG to HA ratio. 
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Biomarker discovery for drug-induced phospholipidosis: 
phenylacetylglycine to hippuric acid ratio in urine and plasma as potential 
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Abstract 
 
Drug-induced phospholipidosis (DIPL) is one of significant concerns in drug safety 
assessment; however, its mechanism and predictive biomarkers are still not well 
elucidated. In this chapter, I have applied metabolomics approach, based on nuclear 
magnetic resonance (NMR), to exploration for novel index that reflects a DIPL status 
using rat urine after administrations of well-known phospholipidosis inducing drugs of 
amiodarone, chloroquine, quinacrine, tamoxifen and fluoxetine, and both hippuric acid 
(HA) and phenylacetylglycine (PAG) levels were well correlated with histopathologic 
changes in DIPL in rats, such as foamy macrophage accumulation and vacuolated 
lymphocyte numbers, and the ratio in plasma was increased in time and dose dependent 
manners. Taking reproducibility of data and convenience for sampling into 
consideration, the ratio of PAG to HA in plasma is expected to be practical marker in 
monitoring DIPL in rats.  
 
  
 17 
 
Introduction 
 
Phospholipidosis (PLD) is a lipid storage disorder in which excess phospholipids 
accumulates within many cell types such as hepatocytes, lymphocytes and macrophages 
(Drenckhahn et al., 1983, Farrell, 2002, Ploemen et al., 2004, Rudmann et al., 2004). 
The risk for drug-induced PLD is one of the significant concerns in drug development, 
especially in safety assessment, because more than 50 cationic amphiphilic drugs 
(CADs), including antidepressants, antianginal, antimalarial, and cholesterol-lowering 
agents, have already been reported to induce PLD so far (Lüllmann et al., 1978, 
Halliwell, 1997, Reasor, 1989). CADs are thought to induce PLD by inhibiting lysosomal 
phospholipase activity, but its mechanism has not been extensively studied and is not 
well understood yet (Hostetler and Matsuzawa, 1981; Joshi et al., 1988; Reasor and 
Kacew, 2001; Xia et al., 2000). Moreover, it is still ambiguous whether drug-induced 
PLD represents benign adaptive responses or toxicity-related events. The absence of a 
non-invasive biomarker has made it difficult to study PLD in vivo. Electron microscopic 
observation has long been employed as the most reliable method for identifying 
phospholipidotic cell damage (Drenckhahn et al., 1976). Since histopathological 
evaluation is relatively non-quantitative, time consuming and an expensive procedure, 
it is considered to be an impractical screening tool for rapid toxicity assessment. 
Furthermore, it is also difficult to monitor PLD in clinical studies without use of an 
invasive methodology such as tissue biopsy. Therefore, development of a non-invasive 
diagnostic tool for PLD is highly desirable in pre-clinical and clinical studies for the 
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development of new drugs.  
Currently there are several candidates for a non-invasive biochemical marker for 
PLD. Since CADs are known to induce PLD in the lymphocytes of animals and humans 
(Lullmann-Rauch, 1979; Dake et al., 1985), vacuolated lymphocytes in peripheral blood 
have been considered as a potential diagnostic biomarker for PLD ( Rudmann et al., 
2004). Using a nuclear magnetic resonance (NMR) based metabolomics approach, 
urinary and plasma phenylacetylglycine (PAG) has been proposed as a potential 
biomarker for PLD (Nicholls et al., 2000); however, the mechanism behind it has not 
been fully elucidated (Delaney et al., 2004). On the other hand, a liquid 
chromatography-mass spectrometry (LC/MS)-based approach identified the elevation of 
serum bis(monoglycero)phosphate (BMP) in PLD induced by drug administration 
(Mortuza et al., 2003); and di-docosahexanoyl (C22:6)-BMP was proposed to be a 
potential marker of drug-induced PLD in rats (Liu et al., 2014). 
So as to be practical biomarker for safety assessment, it is essential to elucidate its 
link to drug-induced toxicity and assess its predictability at least in pre-clinical studies. 
In this report, I have found new biomarker candidates of drug-induced PLD, hippuric 
acid (HA) and phenylacetylglycine (PAG), in rat urine by using NMR spectrometry. 
Then the ratio of urinary PAG to HA was confirmed to reflect the disease state in rats 
with the administration of PLD-inducing drugs. Furthermore, an alternate analytical 
method to determine urinary and plasma concentrations of HA and PAG was 
established with liquid chromatography coupled to tandem mass spectrometry 
(LC/MS/MS) technology. Using the LC/MS/MS-based protocol thus established for 
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robust but convenient quantification, I evaluated the drug-induced alterations in HA 
and PAG levels not only in urine but also in plasma, which can be easily collected in 
monitoring biomarkers for PLD.  
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Materials and Methods 
 
Regents  
Amiodarone, chloroquine, quinacrine and tamoxifen were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Fluoxetine and two reference standards, hippuric 
acid (HA) and phenylacetylglycine (PAG) were purchased from Wako Pure Chemical 
Industries, Ltd. (Osaka, Japan). As the internal standard (IS) in the LC/MS/MS 
analyses, hippuric acid-d5 (HA-d5) was purchased from C/D/N ISOTOPES (Quebec, 
Canada) and phenylacetylglycine-d4 (PAG-d4) was prepared in house. Deuterium oxide 
(D2O) and sodium 3-(trimethylsilyl)-propionate-2,2,3,3,-d4 (TSP-d4) were purchased 
from ISOTEC.INC (Miamisburg, OH, USA). Acetonitrile, methanol (HPLC grade) and 
formic acid, ammonium formate and ammonium acetate (regent grade) were also 
obtained from Wako. All other solvents with the highest purity grades were obtained 
from commercial sources and used without further processing. 
 
Animals 
Five or six weeks old Crl: CD (SD) rats were purchased from Charles River Japan, Inc. 
(Tokyo, Japan). The animals were individually housed in metal cages in a clean booth 
and were allowed free access to tap water and a powdered laboratory diet (CE-2, CLEA 
Japan, Inc., Tokyo, Japan). The racks were placed in an animal room under the 
following conditions: temperature of 20-26 °C, a relative humidity of 40-70%, air 
exchange at 8-25 times/hour and a 12-hour light/dark cycle (lights on from 7:00 a.m. to 
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7:00 p.m.). After s 7-day acclimation period, the animals were randomly assigned into 
control and treatment groups based on their body weight. All the procedures in animal 
handling and bleeding are assessed and approved by Animal Care and Use Committee 
in Takeda Pharmaceutical Company Limited. 
 
Drug administration and sample collection 
Three to five male rats (6-7 weeks old) were used for each dose group. All test 
compounds were suspended in 0.5 w/v % methylcellulose solutions, and the dosing 
suspension was administered in the morning into the stomach of rats via a catheter. 
The vehicle was also administered to control rats in the same manner. The volume 
administered to each animal, 10 mL/kg for each dosage level, was adjusted based on the 
body weight on the first day before dosing.  
For the studies for blood smears, histopathological observation and 1H-NMR analysis, 
amiodarone (100, 300 and 1000 mg/kg/day), chloroquine (25, 75 and 250 mg/kg/day), 
tamoxifen (100, 300 and 1000 mg/kg/day), quinacrine (60, 200 and 600 mg/kg/day) or 
fluoxetine (30, 100 and 300 mg/kg/day) was administered once daily for 3 consecutive 
days. The highest dosing corresponds to approximate 1/2-1/3 of LD50 of each compound. 
After the final dose, urine samples were collected in cooled plastic bottles for 6 hours. 
Drinking water and laboratory diet was removed during urine sampling. The urines 
were centrifuged and resultant supernatants were stored at -70 °C until 1H-NMR 
analysis. Twenty-four hours after the final administration, blood was collected for 
smear preparation and all the animals underwent euthanasia for necropsy examination. 
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For the purpose of acquisition of the toxicokinetic parameters , the respective doses for 
these drugs were administered singly to the other three rats and blood samples were 
collected at 1, 3, 6 and 24 hours after dosing. 
For the LC/MS/MS analysis of urine, rats were dosed once daily for 7 consecutive days 
with amiodarone, chloroquine, tamoxifen or quinacrine (300, 75, 100 and 60 mg/kg/day, 
respectively). After the final administration, the urine samples were collected for 4 
hours during the daytime and stored frozen at -80 ˚C until analysis. For the analysis of 
the plasma, fluoxetine or amiodarone was dosed once daily for 3 consecutive days. 
Fluoxetine was administered at 10, 30 and 100 mg/kg/day and the blood samples were 
collected at 24 hours after the final dosing. On the other hand, blood samples were 
taken serially in the morning (9 am), afternoon (1 pm) and evening (5 pm) on 5 and 3 
days before dosing and then amiodarone was administered at 100 and 300 mg/kg/day at 
9 am. Blood samples were collected consecutively at pre-dosing (9 am), 4 hours (1 pm), 8 
hours (5 pm) and 24 hours after the first and third dosing days. The blood at 48 and 168 
hours after the final dosing was also collected. All the blood samples were collected from 
the tail vein under ether anesthesia and centrifuged to obtain plasma. The resultant 
plasma samples were stored frozen at -80 ˚C until analysis. 
 
Blood smears, histopathology and toxicokinetics 
Blood smears stained with May-Giemsa were examined microscopically to count the 
number of vacuolated lymphocytes out of 300 cells in the microscopic analysis. The 
organs and tissues (lung, lymph node, liver and spleen) from all animals were sampled, 
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examined and fixed in 10 vol % neutral buffered formalin. Brain was also evaluated in 
the chloroquine, fluoxetine or quinacrine-treated groups. The histopathologic 
examination was conducted in a blinded fashion based on the following criteria: foam 
cell infiltration was seen in the lung and the mesenteric lymph nodes, increased tingible 
body macrophages was seen in the spleen and vacuolization was seen in the hepatocytes, 
Kupffer cells and bile duct epithelial cells in the liver, the tubular cells of the kidney and 
cerebellar Purkinje cells. Drug concentrations in plasma were evaluated by 
high-performance liquid chromatography (HPLC) system to calculate the toxicokinetic 
parameters. 
 
1H-NMR spectroscopy and data analysis 
To neutralize the urinary samples, 250 μL of a phosphate buffer solution (0.2 M 
Na2HPO4/0.2 M NaH2PO4, pH 7.4) were added to 500 μL of urine and left to stand for 
10 min. Precipitates was removed by centrifugation at 13,000 rpm for 10 min at 10 °C. 
Aliquots of the clear supernatants (600 μL) were mixed with 60 μL of 11mM 
TSP-d4/D2O solution as an internal standard, then 1H NMR spectra were measured at 
599.59 MHz on a Unity INOVA 600 spectrometer (Varian, Inc. CA, USA) at 298 K. The 
water resonance was suppressed by using 1-D Nuclear Overhauser Enhancement 
Spectroscopy (NOESY) pulse sequence with irradiation during a 1s relaxation delay and 
a 100 ms mixing time. Spectra were acquired using 64 free-induction decays (FIDs) into 
64 K data points, and a spectral width of 8,000 Hz. Exponential line broadening of 0.2 
Hz was applied prior to Fourier transformation. Spectra were phased manually, 
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corrected for baseline distortion and referenced to TSP automatically using an 
ACD/Spec Manager (ACD Labs, Canada). Subsequently all NMR spectra were data 
-0.16 
with region width of 0.04 ppm. The spectral region 4.60-6.12 ppm was excluded to 
remove variability due to suppression of water resonances and cross-saturation effects. 
The intensities of the NMR signals were estimated manually, and normalized using the 
 4.06). 
 
LC/MS/MS and data analysis 
For the preprocessing of the urinary samples for HA and PAG quantification with 
LC/MS/MS, 20 μL aliquots of rat urine were mixed with 10 µL of IS solution and 1 mL of 
water/acetonitrile (1:1, v/v). After removal of precipitants by centrifugation, 20 μL of the 
supernatant were further diluted with 1 mL of solvent (10 mmol/L ammonium 
formate/acetonitrile/formic acid, 475:25:1, v/v/v). In case of the plasma samples, 50 μL of 
aliquots were mixed with 10 μL of IS solution and 450 μL of acetonitrile, centrifuged, 
and then 50 μL of the supernatants were diluted with 150 μL of solvent. The samples 
thus prepared were injected into a LC/MS/MS system, equipped with an SIL-HTc 
autosampler and LC-10ADvp pump system (Shimadzu, Kyoto, Japan). The analytical 
column used was an L-Column ODS (2.1 × 50 mm, 5 μm, Chemicals Evaluation and 
Research Institute, Tokyo, Japan) and the flow rate was 0.2 mL/min at 40˚C. Mobile 
phase A (MP-A) consisted of 10 mmol/L ammonium formate/formic acid (500:1, v/v) and 
mobile phase B (MP-B) consisted of acetonitrile/formic acid (500:1, v/v). The gradient 
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started with 5% MP-B and was linearly increased to 60% within 3 minutes, and then 
increased to 80% for following 0.2 minutes. This condition was kept from 3.2 to 5 
minutes and then it was cycled back to the initial conditions over 0.1 minutes. The total 
analysis time was 10 minutes. Final chromatographic retention times for HA, PAG, 
HA-d5 and PAG-d4 were between 3.5 and 4 minutes.  
The quantification of analytes was performed by electrospray LC/MS/MS in the 
selected reaction monitoring (SRM) mode on a API3000 or API4000 tandem quadrupole 
mass spectrometer with a turbo ion spray configuration, operated in the positive 
ionization mode, with Analyst controlling software (AB Sciex, ON, Canada). Source 
conditions were typically as follows (API3000/API4000): ion spray voltage 4200 V/5200V, 
turbo probe temperature 450 ˚C/550 ˚C, unit resolution on Q1 and Q3. Heated gas (air), 
nebulizer gas (air) and curtain gas (N2) flows were set to 7 or 5, 1.04 L/min/60 unit and 
0.95 L/min/70 unit, respectively. Multipliers were set to 2000 V, and the dwell times for 
HA, PAG and their corresponding ISs HA-d5 and PAG-d4 were 150 ms. For the SRM 
analysis, the following ion transitions were obtained: HA mass-to-charge ratio value 
(m/z) 180 → 105, PAG m/z 194 → 91, HA-d5 m/z 185 → 110 and PAG-d4 m/z 198 → 93. 
Sensitivity was optimized for each compound by varying collision cell pressure, 
declustering potential, focusing potential (for API3000 use only) and collision energy in 
the SRM mode and maximizing ion intensity. The standard curves (50 - 5000 μg/mL for 
HA, 5-1000 μg/mL for PAG in urine, 0.02 - 10 μg/mL for HA and PAG in plasma) gave 
correlation coefficients >0.99 and coefficient of variations ranging within 15%. 
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Statistical analysis 
The mean values of the percentage of vacuolated lymphocytes out of 300 cells for each 
sample in the blood smear, HA and PAG concentrations in the urine and plasma of CAD 
treated animals versus those of control group were compared by Williams test or 
Dunnett multiple comparison test and were considered significant at p < 0.025 and 0.05, 
respectively.   
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Results 
 
Histopathology and toxicokinetics evaluation of PLD-related changes in CAD-treated 
rats 
In one or more organs in the CAD-treated rats, PLD-related histopathological 
changes were observed as follows: accumulation of foamy macrophages in the lungs; and 
medullary sinus of the mesenteric lymph nodes, vacuolization of the hepatocytes, 
Kupffer cell and biliary ducts in the liver, white pulp of the spleen, neurocytes and 
Purkinje cells in the brain (Table1). These histopathological changes were characterized 
by the accumulation of multilamellar bodies and/or accumulation of electron thick dense 
bodies in the cytoplasm of the various cell types as shown in Figure 1. In all the groups 
except for the amiodarone low dose (100 mg/kg), the percentages of vacuolated 
lymphocytes were significantly higher than that in control group and the increase was 
dose-dependent. Therefore, the minimum toxic doses in histopathological evaluation 
were determined to be 300 mg/kg for amiodarone, 25 mg/kg for chloroquine, 100 mg/kg 
for tamoxifen, 60 mg/kg for quinacrine and 30 mg/kg for fluoxetine in a 3-day short term 
exposure. Results of the toxicokinetic parameters in plasma for each CAD compound are 
summarized in Table 3. While the high dose range was selected for the purpose of this 
study, the maximum concentration (Cmax) and the area under the curve (AUC) were 
mostly correlated in a dose dependent manner. 
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Determination of urinary PAG and HA by 1H-NMR analysis 
1H-NMR spectra analysis was carried out for all spectra through normalization of the 
signal intensity by the cre Figure 2 shows 
typical NMR charts indicating the changes in the resonances in rat urine after dosing 
amiodarone (once daily for 3 days). As shown in Figure 2, the results indicated that 
intensities of the resonance 
as hippuric acid (HA), in inverse relation to the dose.  The same tendency was observed 
in all CADs-treated animals. On the other hand, the intensities of the resonances at 
 
phenylacetylglycine (PAG), increased dose-dependently, whose tendency was also 
observed in all CADs-treated animals. The ratios of PAG to HA (PAG/HA ratio) 
calculated from the NMR signal intensity are summarized in Table 2, indicating that 
the values of PAG/HA ratio were significantly higher than that of the control group 
except for the lowest dose groups of amiodarone and chloroquine. The values increased 
in a dose dependent manner in all the CADs-treated animals, and it coincided well with 
the increment in the percentages of vacuolated lymphocytes shown in Table 1. 
 
Quantitative analysis of HA and PAG in urine and plasma by LC/MS/MS 
Since the results obtained through histopathological evaluation and NMR analysis of 
the urine samples suggested to us that the PAG/HA ratio in urine could be a surrogate 
for the PLD-related histopathological changes in CAD-treated rats, I then tried 
quantification of the urinary PAG and HA by LC/MS/MS. After 7 days of multiple oral 
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administration of amiodarone, chloroquine, tamoxifen, or quinacrine (300, 75, 100, 60 
mg/kg/day, respectively) to rats, the concentrations of HA and PAG in urine were 
determined and the PAG/HA ratios were calculated (Figure 3). PAG concentration was 
significantly increased in the amiodarone-treated rats in compared with the controls 
and slightly increased in the rats treated with quinacrine or tamoxifen, but did not 
change in chloroquine treated group (Figure 3B). The same tendency was also observed 
in the PAG/HA ratio (Figure 3C). Although these results supported the idea that the 
PAG/HA ratio indicates the state of PLD, its reliability might be hampered by very large 
inter-individual variability in both urinary PAG and HA concentrations. As is the case 
in other urinary biomarkers, PAG and HA concentrations might require normalization 
with creatinine. 
Since the dynamics of HA and PAG in urine were expected to linked with their plasma 
concentrations, which do not require any normalization, I next performed the 
quantitative determination of HA and PAG in plasma. While the concentrations of HA 
and PAG in plasma were much lower than those in urine, their plasma levels were 
successfully determined by LC/MS/MS. In the amiodarone-treated rats, plasma 
concentrations of HA tended to decrease, those of PAG significantly increased, and the 
ratio of HA to PAG significantly increased in a dose-dependent manner (Figure 4).  
Multiple dosing of fluoxetine also provided the same tendency, PAG/HA ratio in plasma 
was significantly high in 100 mg/kg/day group (Figure 5). Additionally, in our 
preliminary experiments, a toxic dose of phenobarbital as the negative control did not 
change the PAG/HA ratio while imipramine as another PLD inducing drug showed a 
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significant increase of the PAG/HA ratio in plasma. These results of the PAG/HA ratio in 
plasma correlated with the results of the histopathological studies shown in Table 1 and 
those of the PAG/HA ratio in urine determined by 1H-NMR analysis as shown in Figure 
2 and Table 2, indicating the potency of the PAG/HA ratio in plasma as a marker for 
PLD induced by CAD administration. 
 
Intra- and inter-day variation of HA and PAG and time course study after amiodarone 
treatment  
To evaluate time-course changes in the PAG/HA ratio in plasma, amiodarone was 
administrated once daily for 3 consecutive days and blood samples were collected 
serially after the first and third dosing. Concurrently, blood samples were also collected 
5 and 3 days prior to administration to determine the variability of the HA and PAG 
concentrations in the timing of sampling. As shown in Figure 6, the PAG/HA ratio in the 
evening was higher than that of morning due to the decrease in HA but there was no 
increase in the PAG levels. This result strongly suggested to us that it is important to 
match the sampling time point to avoid the influence by daily fluctuations in the HA 
concentrations. The variability of the HA and PAG concentrations and PAG/HA ratio at 
different sampling times and days was checked further with no intervention control 
group (Figure 7), and this result suggests to us that the baseline of PAG/HA ratio is 
stable in the morning.  
The HA and PAG concentrations and PAG/HA ratios in the morning were monitored 
before and after treatment with amiodarone (Figure 8). The PAG/HA ratio showed clear 
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dose and time dependent increases after amiorarone administration. The increment of 
the PAG/HA ratio in the higher dose group (300 mg/kg/day) was sustained after the 
dosing period ended. On the other hand, the ratio in the lower dose group (100 
mg/kg/day) rapidly decreased in a time dependent manner after the dosing period and 
this was consistant with the results from the histopathological evaluation. Trends to 
decrease in HA and increase in PAG levels were observed but were not clear enough to 
show dose-dependency. It was noteworthy that PAG kept increasing in the higher 
dosing group after the dosing period (Figure 8B), and this is considered to contribute to 
the sustained PAG/HA ratio. 
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Discussion 
 
The evidence for the presence of PLD is obtained through histopathological 
examination of animal tissues at pre-clinical stage; however, each CAD tends to induced 
different distribution of PLD as shown in Table 1. Therefore, the mechanism and 
process underlying PLD development are considered to be complex and might differ 
from one drug to another. There are no predictive biomarkers for drug-induced tissue 
PLD other than lymphocyte vacuolation, but morphological observation would not be 
suitable for screening purposes. Therefore, biochemical biomarkers are still being 
explored for drug safety assessment. 
Metabolomics is one of popular technologies in the latest toxicology testing (Robertson 
et al., 2011). To identify biomarker candidates for CAD-induced PLD, I initially 
conducted statistical analysis of the NMR spectra of urinary samples and have 
successfully separated the CAD-dosed groups from the control group by principle 
component analysis. The dominant factors were citrate and α-ketoglutarate, two 
components of Krebs cycle, but it seemed to be difficult to generate a hypothesis for PLD 
mechanism with only these major energy metabolites. Therefore, I pursued manual 
checking of the NMR spectra of urinary samples and found increases in PAG-related 
and decreases in HA-related signals (Figure 2). The increase of PAG in urine matched 
well with the previous report on PAG as biomarker candidate for PLD in rats (Delaney 
et al., 2004, Hasegawa et al., 2007, Doessegger et al., 2013). On the other hand, the 
relationship between PLD and HA had not been elucidated. The key finding of this 
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study was that the ratio of PAG to HA in urine correlated well with CAD-induced PLD. 
LC/MS/MS analysis focused on PAG and HA was applied to urine and plasma, and the 
link between the PAG/HA ratio and PLD was validated. A similar global metabolomic 
approach with LC/MS was applied to the analysis for aristolochic acid-induced 
nephrotoxicity in rats and both PAG and HA were also reported to change concomitant 
with many other metabolites; however, they did not focus on the PAG/HA ratio in their 
analysis (Zhao et al., 2015).  
HA and PAG are known to be metabolites derived from phenylalanine, but the 
metabolic pathway seems to be complicated because of the contribution of microbiota in 
the gut to the process. For example, it is reported that antibiotic-induced bacterial 
suppression reduced the excretion of mammalian-microbial urinary cometabolites 
including HA and PAG (Swann et al., 2011). On the other hand, phenylalanine is 
well-known to be essential amino acid that cannot be synthesized de novo in animals; 
therefore, the amounts of phenylalanine and its metabolites, HA and PAG, in the body 
could also be affected by food intake. The evaluation of the circadian variation in the 
plasma HA and PAG concentrations (Figure 6 and 7) revealed that HA tends to be much 
higher in the morning which corresponded well with the feeding pattern of rats as a 
nocturnal animal. I also have found that plasma concentrations of HA in rats were 
significantly decreased in fasting rats compared with fed rats in a preliminary 
experiment.  
Based on the results in the present study and literature, I propose the hypothesis that 
the catabolism of phenylalanine, as simplistically illustrated in Figure 9, might be 
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perturbed in PLD-induced rats as the mechanism behind the changes in HA and PAG. 
While tyrosine synthesis solely depends on phenylalanine hydroxylase (PAH) at the 
first step, a CAD inducer like amiodarone does not affect the PAH activity (Delaney et 
al., 2004). On the other hand, it is known that phenylalanine is deaminated by 
phenylalanine dehydrogenase to form phenylpyruvate. Phenylpyruvate is further 
metabolized by phenylpyruvate decarboxylase to form phenylacetaldehyde and oxidized 
by aldehyde dehydrogenase to form phenylacetate. Eventually, phenylacetate is 
conjugated with glycine to form PAG to be excreted in rats or conjugated with glutamine 
to form phenylacetylglutamine in human and primates (Doessegger et al., 2013). 
Alternatively, phenylpyruvate is also metabolized to phenyllactate, which is converted 
eventually to form benzoic acid. In this pathway, the cinnamic acid that is formed by 
dehydration of phenyllactate is metabolized to benzoic acid via -oxidation. It is known 
that amiodarone inhibits the mitochondrial -oxidation of fatty acids (Fromenty et al., 
1990; Fromenty and Pessayre, 1995; Kaufmann et al., 2005; Spaniol et al., 2001; 
Waldhauser et al., 2006). Hence, the inhibition of -oxidation in this pathway would 
cause a decrease in HA level. Furthermore, the inhibition of the pathway leading to HA 
might cause a compensatory increase in the alternate metabolic pathway of 
phenylpyruvate, resulting in the increase in PAG. It has been suggested that the 
inhibition of -oxidation is related to a dysfunction in lipid metabolism, which is the 
cause of PLD (Fromenty and Pessayre, 1995). HA decrease and PAG increase in the 
plasma could be an index for inhibition of -oxidation by drugs; therefore, they could be 
a surrogate marker for PLD. Although levels of phenylalanine and its metabolism could 
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be affected by food intake or gut flora (Delaney et al., 2004), the PAG/HA ratio is a 
simple index for the effects on metabolic balance in drug-induced PLD. 
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Tables and Figures 
Table 1. Summary of histopathological changes and vacuolated lymphocyte ratio in 
drug-induced phospholipidosis. 
 
+: Phospholipidosis/steatosis,  -: no abnormality,  ND: not determined 
*: Significantly different from the control group;  p<0.025(Williams) 
  
Histopathology (Plsis/steatosis) Vacuolated lymphocyte (% )
Lung
Lymph
node
Liver Spleen Brain
mean SD
Control 0 mg/kg - - - - ND 1.55 1.32
100 mg/kg - - - - ND 1.25 1.89
300 mg/kg + + - - ND 32.50 5.74 *
1000 mg/kg + + - + ND 39.75 10.24 *
25 mg/kg - + - - - 4.50 1.91 *
75 mg/kg - + - + - 24.25 10.56 *
250 mg/kg - + - + - 66.25 3.94 *
100 mg/kg + + - - ND 20.25 5.85 *
300 mg/kg + + + - ND 38.75 12.20 *
1000 mg/kg + + + - ND 39.50 17.62 *
60 mg/kg + - + - - 14.00 7.75 *
200 mg/kg + + + - - 31.75 9.60 *
600 mg/kg + + + - - 52.33 5.86 *
30 mg/kg + - - - - 7.25 2.87 *
100 mg/kg + + + - + 28.00 10.42 *
300 mg/kg + + + - + 30.75 9.84 *
Tamoxifen
Quinacrine
Fluoxetine
Compound Dose
Amiodarone
Chloroquine
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Table 2. 1H-NMR signal ratio of PAG to HA (PAG/HA ratio) in urine of CAD-treated rats 
 
Results are expressed as the mean ± SD. 
* Significantly different from the control group p< 0.025 (Williams test). 
  
Dose
mg/kg
Control ‐ 0.12 ± 0.04
100 0.16 ± 0.06
300 0.52 ± 0.15*
1000 1.27 ± 0.56*
25 0.15 ± 0.05
75 0.24 ± 0.07*
250 0.69 ± 0.25*
100 0.31 ± 0.07*
300 1.2 ± 0.28*
1000 1.43 ± 0.87*
60 0.28 ± 0.09*
200 0.92 ± 0.38*
600 4.42 ± 2.51*
30 0.19 ± 0.04*
100 0.37 ± 0.19*
300 0.56 ± 0.51*
Fluoxetine
Compounds PAG/HA ratio
Amiodarone
Chloroquine
Tamoxifen
Quinacrine
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Table 3. Pharmacokinetic parameters in plasma after a single administration of CAD 
compounds. 
Results are expressed as the mean ± SD.  
* Plasma concentrations were less than quantification limit through all the 
time-points at 60 mg/kg (n=2) and 200 mg/kg (n=1) in quinacrine dosing groups. 
  
Dose
mg/kg
100 4.0 ± 1.7 1.21 ± 0.70 17.0 ± 8.3
300 2.7 ± 0.0 2.46 ± 0.58 34.3 ± 7.9
1000 2.3 ± 1.2 1.84 ± 0.29 30.3 ± 2.2
25 6.0 ± 0.0 0.05 ± 0.01 0.5 ± 0.1
75 5.0 ± 1.7 0.12 ± 0.03 2.2 ± 0.5
250 5.0 ± 1.7 0.22 ± 0.03 4.4 ± 0.6
100 5.0 ± 1.7 0.85 ± 0.11 13.5 ± 2
300 5.0 ± 1.7 1.37 ± 0.26 25.5 ± 3.8
1000 3.0 ± 0.0 1.85 ± 0.73 33.5 ± 18.9
60 0.01 ± 0.02 0.0 ± 0.1
200 0.04 ± 0.03 0.5 ± 0.5
600 8.7 ± 13.3 0.21 ± 0.11 1.9 ± 0.2
30 2.3 ± 1.2 0.44 ± 0.02 5.3 ± 0.7
100 4.0 ± 1.7 0.76 ± 0.25 12.7 ± 6.7
300 5.0 ± 1.7 1.37 ± 0.20 24.2 ± 3.3
Chloroquine
Compounds
Fluoxetine
Tmax
(h)
Cmax
(μg/mL)
AUC0-24h
(μgh/mL)
Quinacrine*
3.0
13.5
Tamoxifen
Amiodarone
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Figure 1. Vacuolated lymphocyte and foamy cells accumulation in the lung in 
CAD-treated rats. Blood smear (a)CAD-treated rat (b) normal rat: Histopathology of (c) 
CAD-treated rat (d) normal rat. 
 
 
  
 40 
 
Figure 2.  Changes of 1H-NMR signal intensity of rat urine after the last dose of 
amiodarone. 
 
 
  
Figure 2. Changes of NMR signal intensity of rat urine after 3 times oral administration of amiodarone. 
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Figure 3. Urinary concentrations of HA (A) and PAG (B) and concentration ratio of PAG 
to HA (C) after 7-day administration of CADs.  
 
Statistical analysis was performed using Dunnett multiple comparison test; 
significance denoted as *p<0.05, **p<0.01, ***p<0.001 from control. 
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Figure 4. Plasma concentrations of HA (A) and PAG (B) and concentration ratio of 
PAG to HA after 3-day administration of amiodarone.  
 
Statistical analysis was performed using Williams test; significance denoted as # 
p<0.025 from control. 
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Figure 5. Plasma concentrations of HA (A) and PAG (B) and concentration ratio of 
PAG to HA after 3-day administration of fluoxetine.  
 
Statistical analysis was performed using Williams test; significance denoted as # 
p<0.025 from control. 
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Figure 6. Plasma concentrations of HA and PAG and concentration ratio of PAG to HA 
at different time points (9:00 am, 1:00 pm and 5:00pm) 5 and 3 days prior to 
administration. 
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Figure 7. Transition of the plasma concentrations of HA and PAG and concentration 
ratio of PAG to HA in no intervention control group. 
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Figure 8. Plasma concentrations of HA (A) and PAG (B) and concentration ratio of 
PAG to HA (C) before, during and after amiodarone administration.  
 
Statistical analysis was performed using Dunnett multiple comparison test; 
significance denoted as *p<0.05, **p<0.01, ***p<0.001 from control. 
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Figure 9. Metabolic pathway of L-phenylalanine 
 
 
  Fig. 6 Metabolic pathway of L-phenylalanine 
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Chapter 2 
 
Method development and validation for simultaneous quantitation of 
endogenous hippuric acid and phenylacetylglycine in rat urine using liquid 
chromatography coupled with electrospray ionization tandem mass 
spectrometry 
  
 49 
 
Abstract 
 
Urinary hippuric acid (HA) and phenylacetylglycine (PAG) are biomarker candidates 
for drug-induced phospholipidosis (PLD). To confirm their utility in preclinical and 
clinical settings, it is essential to develop and validate their quantification method in 
advance. In this chapter, I have applied liquid chromatography-tandem mass 
spectrometry (LC/MS/MS) for simultaneous quantification of HA and PAG in rat urine, 
and matrix based ion suppression was assessed by post-column infusion assay. Effective 
sample dilution reduced matrix effect of urine to be negligible level and calibration 
curves showed good correlation between those in urine diluent and buffer alone. 
Reliability of this assay was confirmed by the assessments for intra- and inter-day 
precisions and accuracies of quality control samples. The method was applied to rat 
urine after multiple oral administrations of PLD-inducing drugs, and the changes in HA 
and PAG concentrations and their ratio were successfully detected. This assay would be 
useful tool for monitoring PLD in toxicological studies by non-invasive sampling. 
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Introduction 
 
Phospholipidosis (PLD) is a lysosomal storage disorder to accumulate excessive 
amounts of phospholipids within diverse cell types (Drenckhahn et al., 1983, Farrell, 
2002, Ploemen et al., 2004, Rudmann et al., 2004) and then organs/tissues affected by 
PLD exhibit histopathological changes and inflammatory reactions. The primary 
characteristic of PLD is cytoplasmic vacuoles observed by standard histopathological 
examination, but the authentic morphological hallmark of PLD is the appearance of 
multilamellar bodies under electron microscope finding. Since lysosomes are organelle 
responsible for metabolizing waste materials to be excreted, the substances which are 
normally broken down and excreted would be trapped inside the cells under PLD. 
Risk for PLD induction is one of significant concerns in drug development, as it is 
called drug-induced PLD (DIPL); because more than 50 cationic amphiphilc drugs 
(CADs), including antidepressants, antianginal, antimalarial, and cholesterol-lowering 
agents, have been reported to induce PLD not only in animals but also in humans 
(Lüllmann et al., 1978, Halliwell, 1997, Reasor, 1989). DIPL and its progress are 
difficult to monitor due to invasive nature of tissue samples acquisition and it is not 
possible to predict which tissues will be affected. In most cases, risk of DIPL has been 
first identified in histopathological examination, as a part of general toxicity studies at 
late discovery stage. To select lead and develop candidate compounds without PLD 
concern at earlier stages, readily accessible biomarker is preferred for routine 
assessment. Vacuolated lymphocyte in the peripheral blood is useful screen for the 
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detection of PLD (Drenckhahn et al., 1976), but it requires histopathological skills for 
quantification. Biochemical index has long been explored and 
bis(monoglycero)phosphate (BMP) and phenylacetylglycine (PAG) were proposed as 
potential biomarkers for PLD (Mortuza et al., 2003, Nicholls et al., 2000). The specificity 
and mechanistic relevance of these biomarkers with DIPL have been explored (Delaney 
et al., 2004, Mesens et al., 2012), but there still remain some limitation in applying 
them as authentic DIPL markers. I have identified dose-dependent increase of PAG and 
concomitant decrease of hippuric acid (HA) in urine and plasma of CADs-treated rats by 
1H-NMR analysis. PAG, HA and PAG/HA ratio was well correlated with 
histopathological changes in PLD in rats. Phenylalanine is known to be a precursor for 
both HA and PAG, its two major metabolic alterations, such as inhibition of 
beta-oxidation at phenylalanine to HA pathway by PLD-inducing drugs and 
concomitant acceleration of a compensation pathway to PAG, are considered to be 
underlying mechanism for the change in PAG to HA ratio. Taking reproducibility of data 
and convenience for sampling into consideration, the ratio of PAG to HA in plasma was 
validated further to be practical marker in monitoring drug-induced PLD in rats. On 
the other hand, their application to routine measurement of urinary sample is still 
needs some optimization. 
In general, single urinary biomarker measurements require to be presented as ratio 
to urinary creatinine to control for variations in urine volume excreted (Wasung et al., 
2015). The simultaneous measurement for PAG to HA ratio might enable us to skip 
normalization process, because ratio to urinary creatinine for each metabolite can be 
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compensated in the calculation. On the other hand, the degree of accuracy in absolute 
quantification of each metabolite is still remaining as technical issue even in PAG to HA 
ratio measurement. Since coexisting substances interfere with urinary metabolite to 
hamper sensitivity and selectivity, pre-analytical sample processing needs to be 
incorporated into analytical procedure. Dilution would be preferred rather than 
extraction, because recovery rate needs to be argued in any of extraction procedures. 
Therefore, selection of appropriate matrix for sample and standard dilution would also 
be important in establishing reliable method.  
There are several publications to quantify HA and other metabolites with various 
separation and detection procedures (Laryea et al., 2010, Moein et al., 2014, Remane et 
al., 2015) . On the other hand, only a few publications are reported for quantification of 
PAG in biofluids (Stanislaus et al., 2012) and there are no reliable simultaneous 
quantification procedure for HA and PAG. In this chapter, I describe development of a 
method for simultaneous quantification of rat urinary HA and PAG as potential 
biomarkers for DIPL using high-performance liquid chromatography/tandem mass 
spectrometry (LC/MS/MS). Degree of matrix based ion suppression and linearity of 
calibration curve were assessed in addition to robustness and reproducibility. The 
method was also validated with representative CADs known to induce PLD. 
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Materials and Methods 
 
Regents  
Hippuric acid (HA) and phenylacetylglycine (PAG) were purchased from Wako Pure 
Chemical Industries, Ltd. (Osaka, Japan) as reference standards. Hippuric acid-d5 
(HA-d5) was purchased from C/D/N ISOTOPES (Quebec, Canada) and 
phenylacetylglycine-d4 (PAG-d4) was prepared in house as internal standards (ISs). 
Amiodarone, imipramine and tamoxifen were obtained from Sigma-Aldrich (St. Louis, 
MO, USA). HPLC grade acetonitrile, methanol, and regent grade formic acid, 
ammonium formate and ammonium acetate were obtained from Wako. All other 
solvents with the highest purity grades were purchased from commercial suppliers and 
used without further processing. 
 
Animals 
Five weeks old Crl: CD (SD) rats were purchased from Charles River Japan, Inc. 
(Tokyo, Japan). The animals were individually housed in metal cages in a clean booth 
and were allowed free access to tap water and a powdered laboratory diet (CE-2, CLEA 
Japan, Inc., Tokyo, Japan). The racks were placed in an animal room under the 
following conditions: temperature of 20-26 °C, a relative humidity of 40-70%, air 
exchange at 8-25 times/hour and a 12-hour light/dark cycle (lights on from 7:00 a.m. to 
7:00 p.m.). After 7 days acclimation period, animals were randomly assigned into 
control and treatment groups based on body weight. All the procedures in animal 
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handling are assessed and approved by Animal Care and Use Committee in Takeda 
Pharmaceutical Company Limited. 
 
Drug administration and urine sample collection 
Four male rats (6 weeks old) were used for each dosing group. All test compounds 
were suspended in 0.5 w/v % methylcellulose solutions, and the dosing suspension was 
administered in the morning into the stomach of rats via catheter. The vehicle was also 
administered to control rats in the same manner. The volume administered to each 
animal, 10 mL/kg for each dosage level, was adjusted based on the body weight on the 
first day before dosing.  
The test compounds were administered once daily for 7 consecutive days with 
amiodorone (300 mg/kg/day), chloroquine (75 mg/kg/day), tamoxifen (100 mg/kg/day), 
quinacrine (60 mg/kg/day), perhexiline (200 mg/kg/day) or imipramine (100 mg/kg/day). 
After the final administration, the urine samples were collected for 4 hours during the 
daytime and stored frozen at -80 ˚C until analysis.  
 
Preparation of standard solutions 
HA and PAG stock solutions, containing 10 mg/mL HA or 1 mg/mL PAG in 
acetonitrile/water (1:1, v/v), were mixed and serially diluted in acetonitrile/water (1:1, 
v/v) to prepare standard solution ranging from 50 to 5000 μg/mL for HA and 5 to 500 
μg/mL for PAG. PAG stock solution was also used as 1000 μg/mL standard solution. A 
mixture of 1000 μg/mL HA-d5 and PAG-d4 working solution for IS was prepared in 
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acetonitrile/water (1:1, v/v). 
 
Sample preparation 
Twenty micro liters of 6 individual rat urine for matrix-based calibration standard or 
10 mmol/L ammonium acetate buffer for buffer-based calibration standard were mixed 
with 10 μL of the IS solution, 20 μL of each standard solution (in the case of calibrators), 
or water/acetonitrile (1:1, v/v, unspiked urine samples), and diluted with 1 mL of 
water/acetonitrile (1:1, v/v). After mixing and centrifugation, 20 μL of the supernatant 
was further diluted with a 1 mL of a mixture of mobile phases (MP-A/MP-B, 95:5, v/v). 
The diluted solution was injected into a LC/MS/MS system. 
For preparing quality control samples (QCs), the initial control rat urine sample 
determined the concentration from the buffer-based calibration curve was qualified as 
QC-I. Two hundred forty micro liter and 60 μL of a mixture of 5000 μg/mL of HA and 
500 μg/mL of PAG solution was evaporated under a stream of nitrogen gas and the 
residue was dissolved in 600μL of QC-I to provide the QC-H (QC-I + 2000 μg/mL for HA, 
QC-I + 200 μg/mL for PAG) and QC-M (QC-I + 500 μg/mL for HA, QC-I + 50 μg/mL for 
PAG), respectively. The QC-H sample was diluted 20-fold in 10 mmol/L ammonium 
acetate solution to prepare QC-L ((QC-I + 2000)/20 μg/mL for HA, (QC-I + 200)/20 
μg/mL for PAG). To investigate matrix effect using a post column infusion system, three 
different dilution rate urine samples and no matrix sample were prepared. Twenty 
micro liters of 6 individual rat urine or 10 mmol/L ammonium acetate solution were 
diluted according to the sample preparation method described above except for addition 
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of standard solution and IS solution to obtain c.a. 2700-fold diluted urine and its 
matrix-free sample. Other individual aliquots of 20 μL of the rat urine were diluted with 
80 or 980 μL of mixture of mobile phases (MP-A/MP-B, 95:5, v/v) to prepare 5 and 
50-fold diluted urine samples, respectively. 
 
Mass spectral instrumentation 
The quantification of the analytes was performed by electrospray LC/MS/MS in the 
selected reaction monitoring (SRM) mode on a API3000 tandem quadrupole mass 
spectrometer (MDS SCIEX, ON, Canada) with a turbo ion spray configuration, operated 
in the positive ionization mode, with Analyst controlling software. Source conditions 
were typically as follows: ion spray voltage 4200 V, turbo probe temperature 450 ˚C, unit 
resolution on Q1 and Q3. Heated gas (air), nebulizer gas (air) and curtain gas (N2) flows 
were set to 7, 1.04 and 0.95 L/minutes, respectively. Multipliers were set to 2000 V, and 
the dwell times for HA, PAG and their corresponding ISs HA-d5 and PAG-d4 were 150 
ms. For the SRM analysis, the following ion transitions were obtained: HA 
mass-to-charge ratio value (m/z) 180 → 105, PAG m/z 194 → 167, HA-d5 m/z 185 → 110 
and PAG-d4 m/z 198 → 93. Sensitivity was optimized for each compound by varying 
declustering potential, focusing potential and collision energy in the SRM mode and 
maximizing ion intensity. For our instrument, at a collision cell pressure of 12 bit (N2), 
declustering potential, focusing potential and collision energy were typically as follows: 
HA 21 V, 150 V, 17 V, PAG 26 V, 120 V, 29 V, HA-d5 21 V, 100 V, 19 V, and PAG-d4 26 V, 
150 V, 25 V. 
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HPLC separation method 
For the quantitative method, a liquid chromatography system was composed of a 
Shimadzu (Kyoto, Japan) SIL-HTc autosampler and LC-10ADvp pump system. The 
analytical column was a Chemicals Evaluation and Research Institute (Tokyo, Japan) 
L-Column ODS (2.1 × 50 mm, 5 μm) at a flow rate of 0.2 mL/minuets at 40˚C. Mobile 
phase A (MP-A) consisted of 10 mmol/L ammonium formate/formic acid (500:1, v/v) and 
mobile phase B (MP-B) consisted of acetonitrile/formic acid (500:1, v/v). The gradient 
started with 5% MP-B and linearly increased to 60% within 3 minutes, then increased 
to 80% for following 0.2 minutes. This condition was kept from 3.2 to 5 minutes and 
then it was cycled back to the initial conditions over 0.1 minutes. The total analysis 
time was 10 minutes. Final chromatographic retention times for HA, PAG, HA-d5 and 
PAG-d4 were between 3.5 and 4 minutes. To confirm the specificity of the assay, 
additional two columns of different separation mode were also used. A CAPCELL PAK 
UG120 Ph column (2.0 × 50 mm, 5μm, Shiseido, Co. Ltd., Tokyo, Japan) and CAPCELL 
PAK UG80 NH2 column (2.0 × 50 mm 5μm, Shiseido) were used under the same LC 
gradient condition described above. 
 
Post-column infusion method 
The purpose of the post-column infusion examination is to verify the validity of the 
quantification of endogenous components in urine by using buffer-based caliburation 
curves. A post column infusion system was used on the quantitative analysis method. 
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Ten micro liters of different dilution rate urine samples and matrix-free solvent were 
injected into the LC/MS/MS system. A mixture of 1 μg/mL HA-d5 and PAG-d4 in 
acetonitrile/water (1:1, v/v) solution were continuous infused with a Harvard Pump 11 
syringe pump (South Natic, MA, USA) at a flow rate of 10 μL/minutes between the 
analytical column and the MS source.   
 
Quantification 
Peaks on the chromatograms, detected using the SRM mode, were identified based on 
the retention time and the mass number of the monitoring ions. The concentrations of 
HA and PAG were determined from the peak area ratios of the analytes to each IS using 
the internal standard method. The calibration curve was obtained by a 1/C weighted 
least-squares linear regression on the ratios of the peak areas of the analytes to those of 
the IS versus the theoretical concentrations of the analytes in the buffer based 
calibration standards: 
Y = a × Ctheor + b, 
where Y, Ctheor, a, and b are the peak area ratio, the spiked concentration of the 
analyte, the slope, and the Y-intercept, respectively.  The concentrations of HA and 
PAG in rat urine (Cobs) were calculated from the equation for the calibration curve of 
each analyte: 
Cobs = (Y - b) / a 
The linearity of the method was investigated using the sample preparation procedure 
described above for HA and PAG. Buffer-based calibration curves (eight points) were 
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prepared in concentration ranges of 50-5000 μg/mL for HA and 5-1000 μg/mL for PAG. 
Precision, accuracy and stability were determined by running standard QCs at four 
different concentrations covering the calibration range, on the same (intra-day) and on 
different days (inter-day variability).  
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Results 
 
Specificity of SRM chromatogram targeting HA and PAG in urine 
At first, I have checked whether there were any other peaks overlapping with HA and 
PAG in LC/MS/MS chromatogram of rat urine, which makes quantitative analysis 
difficult. Five individual rat urine samples were analyzed by LC/MS/MS system 
equipping three columns of different functional groups (octadecylsilyl, phenyl and 
amino). In each SRM chromatogram targeting HA and PAG, there was no notable peak 
except for the peaks corresponding to HA and PAG. These findings strongly indicated 
that the peaks detected at SRM channel selected for HA and PAG were free of 
interfering components. 
 
Assessments of matrix effect 
Matrix-dependent signal suppression or enhancement (matrix effect) is a major 
drawback in quantitative analysis by LC/MS/MS. In this study, the extent of matrix 
effect and assay reliability were assessed by following two experiments: (1) monitoring 
post column infused HA and PAG at corresponding SRM channel with the subsequent 
injection of serially diluted urine or buffer, (2) comparison of the slopes of calibration 
curves in the presence or absence of urine. 
In the first experiment, deuterium-labeled HA and PAG (HA-d5 and PAG-d4, Figure 
10) were used as tracers for SRM to differentiate signals from those of endogenous HA 
and PAG in urinary sample. HA-d5 and PAG-d4 solution were continuously infused, and 
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then diluents of rat urine (5-, 50-, 2700-fold) or buffer alone were injected into the 
LC/MS/MS system. SRM channels selected were m/z 185 → 110 for HA-d5 and m/z 198 
→ 93 for PAG-d4. Figure 11 shows schematic of the post column infusion experimental 
set up. Ion suppression which was attributed to urinary matrix was estimated by the 
comparison of SRM chromatograms; and typical post column infusion chromatograms 
for each analyte were shown in Figure 12. At the retention time of approximately 3.5-4.0 
minutes, corresponding to those of HA and PAG, significant signal suppression was 
observed by the injections of 5- and 50-fold urinary diluents. On the other hand, the 
chromatogram of 2700-fold diluted urine was almost identical to that of buffer alone 
except for earlier (approximately 1 min) timing. The integrated ion intensity ratios for 
HA-d5 and PAG-d4 within 3.5-4.0 minutes window were 99.7% and 101.7% (against 
buffer alone) for the 2700-fold diluted urine samples, whereas the 50-fold and 5-fold 
diluted samples showed 58.3% and 32.5% for HA-d5 and 68.0% and 30.2% for PAG-d4, 
respectively. Urines from six individual rats showed same trend; therefore, ion 
suppression by matrix effect of urine would be able to be excluded in this sample 
preparation procedure with an appropriate dilution. 
Next, I have assessed the interference with slopes of calibration curves by urinary 
matrix. Calibration curves were obtained with matrix (2700-fold diluted urine)-based 
and buffer-based standards as a pair for six individual rats and serially diluted 
standards (50-5000 μg/mL for HA and 5-1000 μg/mL for PAG). As shown in Table 4, the 
slopes for HA and PAG thus obtained were almost identical regardless of the presence of 
matrix. Y-intercepts of matrix-based calibration curves for HA and PAG were higher 
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than those of buffer-based calibration curves due to the presence of the endogenous HA 
and PAG. These endogenous HA or PAG were calculated by dividing Y-intercept by slope, 
and compared with the quantified value calculated from the buffer-based calibration 
curve (Table 5). The concentrations thus calculated matched well in each pairs; 
therefore, buffer-based calibration standards can be used to determine the quantity of 
HA and PAG in rat urine instead of matrix-based calibrations. 
 
Linear range and accuracy 
The linearity of buffer-based calibration curves were also assessed within the ranges 
50-5000 μg/mL for HA and 5-1000 μg/mL for PAG. The precision and accuracy of the 
data for intra- and inter-day variability were evaluated using quality control samples 
(QCs) prepared with n=5 at four different concentration levels, covering the calibration 
ranges used for HA and PAG. Back-calculated HA and PAG concentrations of the quality 
control samples assayed in three separate runs are shown in Table 6. The intra-day 
precision (coefficient of variation, C.V.) and accuracy (relative error, R.E.) were between 
0.8 to 1.9% and -5.3 to -0.5% for HA and between 1.3 to 2.7% and -6.1 to -3.7% for PAG, 
respectively. Inter-day precision and accuracy ranged between 0.8 to 2.2% (C.V.) and 
-4.8 to -1.9% (R.E.) for HA and between 0.6 to 3.0% (C.V.) and -4.2 to -3.1% (R.E.) for 
PAG, respectively. Therefore, the assay was confirmed to be very robust and 
reproducible. 
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Stability assessments 
The stability of HA and PAG in stock solution, biological matrix, and analytes for 
LC/MS/MS analysis were evaluated. Stock solutions and working solutions of HA, PAG, 
HA-d5 and PAG-d4 in water/acetonitrile (1:1, v/v) were confirmed to be stable for 24 h at 
room temperature and for 45 days at 5 ˚C. The analytes were stable for 49 h in the glass 
assay vial set in the autosampler at 10 ˚C. In rat urine, HA and PAG were stable for 24 
h in an ice-water bath and for 60 days at -80 ˚C. At least three freeze and thaw cycles 
did not show any interference with stability of HA and PAG. 
 
Method comparison 
Since HA is one of the major endogenous components of urine, there are several 
quantitative analytical methods for HA with various separation and detection 
procedures of HPLC-DAD, GC/MS and LC/MSMS (Laryea et al., 2010, Moein et al., 
2014, Remane et al., 2015). GC/MS analysis needs time consuming sample 
derivertization process and HPLC-DAD method often has a problem of lack of specificity 
compared with MS detection method. Regarding LC/MS/MS analysis, the critical issue 
for this method development is to avoid the matrix based ion surpression and to meet 
the situation authors adopted unique sample extraction/dilution procedures. However 
there still have problems concerning analytical robustness or validity of using 
alternative blank matrix (Laryea et al., 2010, Moein et al., 2014). My analytical 
procedure in this report precisely demonstrated the assay validity by specificity 
confirmation, matrix effect evaluation and intra- and inter-day assay validation for HA 
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and PAG simultaneously. 
Application to toxicology study in rats 
The method was applied to diagnose PLD state in the toxicity study. After multiple 
oral administration of PLD inducing drugs to rats, the concentrations of HA and PAG in 
urine were determined by the described method (Figure 13). The mean urinary 
concentrations of HA treated with amiodarone, chloroquine, tamoxifen, quinacrine, 
perhexiline and imipramine were 894.9, 1054.7, 800.3, 869.3, 1207.2 and 888.9 μg/mL, 
respectively, which were slightly lower than that of control samples (1401.3 μg/mL). The 
concentrations of PAG treated with amiodarone (765.9 μg/mL) was significantly higher 
than that of control samples (92.5 μg/mL), and PAG level treated with chloroquine, 
tamoxifen, quinacrine, perhexiline and imipramine were 89.2, 292.6, 188.0, 132.0 and 
291.9 μg/mL. Although the concentrations of HA and PAG after drug treatment except 
for PAG in amiodarone group were not significant compared with control group, The 
increase trend for HA and decrease trend for PAG were observed. The proportions of the 
PAG to HA in amiodarone group were also significantly higher than that of control. We 
assumed its reliability might be hampered by very large inter-individual variability in 
both urinary PAG and HA concentrations. As is the case in other urinary biomarkers, 
normalization with creatinine should be required. 
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Discussion 
There have been two hypotheses to explain the mechanisms underlying DIPL; the 
first one is direct binding of CADs to phospholipids to form indigestible complex by 
lysosome (Halliwell, 1997) and the other one is inhibition of phospholipase activity by 
the formation of lamellar body in lysosome (Reasor and Kacew, 2001). They were based 
on possible interaction of CADs to phospholipid layer of the lysosome, but both of them 
are not sufficient to predict which metabolic pathway and tissues will be affected by 
DIPL. Under such circumstances, the biomarker for DIPL is still limited to the 
consequence of histopathological change even though it is identified to be biochemical 
metrics. For example, di-docosahexaenoyl (22:6)- Bis(monoacylglycerol)phosphate 
(di-22:6-BMP) was reported to be a reliable biomarker of DIPL that can be monitored in 
the plasma and urine (Baronas et al., 2007, Mesens et al., 2012, Tengstrand et al., 
2010); however, BMP is a lysosomal phospholipid which is practically identified to 
increase in the damaged tissues of animals and humans with DIPL and Niemann–Pick 
type C (NPC) disease (Besley and Elleder, 1986, Harder et al., 1984, Rouser et al., 1968, 
Tengstrand et al., 2010). Recently, I have identified that PAG, HA and their ratio in 
plasma and urine can be biomarker for DIPL and implicated their possible link to the 
inhibition of β-oxidization by metabolomic approach (Kamiguchi et al., 2016). Since 
phenylalanine is the precursor for PAG and HA, catabolism of phenylalanine might be 
perturbed by CADs as discussed previously (Kamiguchi et al., 2016).  
The plasma PAG/HA showed good correlation with CAD-induced PLD, however, 
urinary sample showed large inter-individual variability in the previous study 
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(Kamiguchi et al., 2016). Normalization with creatinine might be one possible solution, 
but the degree of accuracy in absolute quantification of each metabolite is another 
technical issue. In this study, we have identified that coexisting substances in urine 
interfere with PAG and HA to hamper their sensitivity and selectivity by post-column 
infusion SRM chromatograms (Figure 12). Pre-analytical sample processing might need 
to be incorporated into analytical procedure but dilution with the buffer successfully 
reduced sample ion suppression to negligible level. The calibration curve generated with 
buffer-based dilution series showed good linearity with those from matrix (urine)-based 
dilution. The robustness and reproducibility were also confirmed by intra- and inter-day 
precision and accuracy tests. Finally, the method was successfully applied to rat urine 
after multiple oral administrations of drugs which induce PLD and the PAG to HA ratio 
were clearly higher than that of control (Figure 13). From the viewpoint of animal 
welfare, screening for DIPL risk with spot urine is preferred because it can be set as a 
part of routine pharmacology study but not independent toxicology test. 
In silico analyses and in vitro assays were also proposed to detect or screen potential 
phospholipogenic compounds (Chatman et al., 2009). As a whole, standardized strategy 
for risk management of DIPL has long been highly desired but uncertainness of the 
pathological significance of DIPL hampers its establishment (Chatman et al., 2009). In 
addition to it, only a few compounds such as amiodarone, gentamicin, chloroquine, 
4,4-diethylaminoethoxyhexestrol and telithromycin has been reported to cause 
concurrent toxicity with PLD in humans (Chatman et al., 2009); and, this makes the 
situation to be highly complicated. Therefore, disease pathway analyses of DIPL with 
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these toxic compounds on humans would still be indispensable; and biomarkers selected 
would be keys for them. It might not be absolutely consistent in experimental condition 
and sample matrix but plasma PAG to HA ratio increased prior to di-22:6-BMP 
increment in urine of amiodarone treated rat (Liu et al., 2014). Since the focus of this 
study is to establish quantitation method and its validation, time course study with 
urinary sample has not been conducted. Further studies with combinatory use of 
urinary PAG to HA ratio and di-22:6-BMP as biomarkers would enables us to 
understand DIPL process further; and, would be base for understanding concurrent 
toxicity with PLD in humans. 
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Tables and Figures 
Table 4. Comparison of slopes for HA (A) and PAG (B) between the buffer-based 
standard curves and matrix-based standard curves obtained from six individual rat 
plasma. 
 
  
b/a
Buffer-based standard (a)
Matrix- based standard
(b)
(%)
1 0.0021062 0.0021322 101.2
2 0.0021062 0.0020863 99.1
3 0.0021062 0.0022252 105.6
4 0.0021326 0.0021068 98.8
5 0.0021326 0.0020765 97.4
6 0.0021326 0.0021011 98.5
Mean 0.0021214
S.D. 0.0000543
C.V. (%) 2.6
b/a
Buffer-based standard (a)
Matrix- based standard
(b)
(%)
1 0.0020456 0.0020753 101.5
2 0.0020456 0.0020839 101.9
3 0.0020456 0.0020796 101.7
4 0.0020331 0.0020599 101.3
5 0.0020331 0.0020785 102.2
6 0.0020331 0.0021024 103.4
Mean 0.0020799
S.D. 0.0000138
C.V. (%) 0.7
No.
Slope
No.
Slope
(A)
(B)
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Table 5. Comparison of the concentrations of endogenous HA (A) and PAG (B), 
calculated from buffer-based standard curves and matrix-based standard curves. 
 
  
b/a
Buffer-based standards
(a)
Matrix-based standards
(b)
(%)
1 2310 2240 97.0
2 1990 2040 102.5
3 2210 2060 93.2
4 2000 2040 102.0
5 1970 2050 104.1
6 2020 2030 100.5
b/a
Buffer-based standards
(a)
Matrix-based standards
(b)
(%)
1 90.9 90.3 99.3
2 117 116 99.1
3 76.0 78.1 102.8
4 111 110 99.1
5 108 106 98.1
6 109 105 96.3
No.
Concentration (μ g/mL)
No.
Concentration (μ g/mL)
(A)
(B)
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Table 6. Back-calculated HA and PAG concentrations of quality control samples 
assayed in three separate batch runs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Concentration (μg/mL) 
 
Day 1 (Intra-day) Day 2 Day 3 
CHA 4140 2640 4140 CHA 4160 2660 4160 CHA 4080 2580 4080 No. Nominal 
(QC-I) (QC-L) (QC-M) (QC-H) 
 
(QC-I) (QC-L) (QC-M) (QC-H) 
 
(QC-I) (QC-L) (QC-M) (QC-H) 
1  2180 4040 2550 3810  2160 4080 2500 3960  2100 4140 2620 4040 
2  2130 4110 2590 3960  2200 3920 2540 3910  2010 4130 2590 3950 
3 Observed 2170 4120 2590 3900  2110 4090 2460 3890  2090 4200 2470 3950 
4  2070 4150 2570 3940  2180 3700 2620 3820  2160 4130 2540 3970 
5  2140 4190 2570 3970  2170 3950 2490 3940  2060 3810 2510 3890 
Mean (n=5) 2140 4120 2570 3920  2160 3950 2520 3900  2080 4080 2550 3960 
S.D.   40  60   20   70    30  160   60   50    60  150   60   50 
C.V.(%) 1.9 1.5 0.8 1.8  1.4 4.1 2.4 1.3  2.9 3.7 2.4 1.3 
R.E.(%) - -0.5 -2.7 -5.3  - -5.0 -5.3 -6.3  - 0.0 -1.2 -2.9 
             
 Inter-day Concentration (μg/mL) 
CHA 4130 2630 4130      
 (3 days) Nominal 
(QC-I) (QC-L) (QC-M) (QC-H)      
 Mean (n=3)  2130 4050 2550 3930      
 S.D.    40   90   30   30      
 C.V. (%)  1.9 2.2 1.2 0.8      
 R.E. (%)    - -1.9 -3.0 -4.8      
QC-L values were corrected with dilution factor, 20. 
 
Concentration (μg/mL) 
 
Day 1 (Intra-day) Day 2 Day 3 
CPAG 310 161 310 CPAG 308 159 308 CPAG 308 159 308 No. Nominal 
(QC-I) (QC-L) (QC-M) (QC-H) 
 
(QC-I) (QC-L) (QC-M) (QC-H) 
 
(QC-I) (QC-L) (QC-M) (QC-H) 
1  112 285 153 301  106 306 154 294  110 269 148 292 
2  115 300 154 300  107 305 156 290  110 287 158 311 
3 Observed 107 285 158 296  116 307 155 291  107 291 149 298 
4  110 287 151 301  105 300 154 297  109 316 155 298 
5  109 297 157 291  112 312 159 297  107 289 158 316 
Mean (n=5) 111 291 155 298  109 306 156 294  109 290 154 303 
S.D.   3   7   3   4    5   4   2   3    2  17   5  10 
C.V.(%) 2.7 2.4 1.9 1.3  4.6 1.3 1.3 1.0  1.8 5.9 3.2 3.3 
R.E.(%) - -6.1 -3.7 -3.9  - -0.6 -1.9 -4.5  - -5.8 -3.1 -1.6 
             
 Inter-day Concentration (μg/mL) 
 CPAG 309 160 309      
 
(3 days) Nominal 
(QC-I) (QC-L) (QC-M) (QC-H)      
 Mean (n=3)  110 296 155 298      
 S.D.    1   9   1   5      
 C.V. (%)  0.9 3.0 0.6 1.7      
 R.E. (%)    - -4.2 -3.1 -3.6      
QC-L values were corrected with dilution factor, 20. 
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Figure 10. Chemical structures of HA, PAG, HA-d5 and PAG-d4 
 
 
  
Phenylacetylglycine
(PAG)
MW 193
N
H
O
O
OH
Hippuric acid
(HA)
MW 179
H
N
O
O
OH
Phenylacetylglycine-d4
(PAG-d4)
MW 197
N
H
O
O
OH
Hippuric acid-d5
(HA-d5)
MW 184
H
N
O
O
OH
D
D
D
D
D
D
D
D
D
 72 
 
Figure 11. Scheme of the post-column infusion instrumentation 
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Figure 12. Post-column infusion SRM chromatograms for HA-d5 (A), and PAG-d4 (B) 
obtained after injecting diluted rat urine and buffer samples. These chromatograms are 
plotted the mean intensity of six individual rat urine samples. 
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Figure 13. Urinary concentrations of HA and PAG (A) and proportions of the PAG to 
HA (B) after multiple administrations of PLD inducing drugs.  
 
 
 
Statistical analysis was performed using Dunnett's multiple comparison test; 
significance denoted as **p<0.01, ***p<0.001 from control. 
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General Discussion 
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In this thesis, I investigated the potential biomarkers in non-invasive way to monitor 
the status of drug-induced phopholipidosis with a metabolomics approach. In Chapter 1, 
the biomarker exploration study in urine and plasma of rats after administrations of  
various PLD inducing drugs was investigated to discover the changes in PAG to HA 
ratio were well correlated with histopathologic changes in DIPL. I discussed the 
hypothesis of the metabolic perturbation of phenylalanine as precursor component of 
both HA and PAG. In Chapter 2, a simultaneous quantification methods for HA and 
PAG in rat urine was developed and validated using LC/MS/MS and discussed the 
advantage of combination of the two metabolic components to use as DIPL biomarker in 
a biological aspect. 
DIPL is one of significant concerns for medication not only in drug research and 
development process but also in medical front. Especially, diagnosis and prognosis of 
DIPL at earlier stage by non-invasive method are still challenging because its 
mechanism and predictive biomarkers are not well elucidated. In Chapter 1, I firstly 
investigated the histopathological examination with well-known PLD inducing drugs of 
amiodarone, chloroquine, tamoxifen, quinacrine and fluoxetine. The result showed that 
each drug tends to induce toxicity in different tissues that is assumed the different drug 
distribution and molecular mechanism. One of the concepts of biomarkers from 
biological fluids like urine, blood and plasma is some biological signatures of 
pharmacological changes in a body should be reflected in systemic circulation or 
excretion. Metabolomics approach in this study successfully discovered HA and PAG as 
potential biomarkers of DIPL from rat urine and plasma. Since these endogenous 
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components are natively regulated for maintaining the fundamental vital processes, 
these levels are affected by not only the drug effect but also complex biological 
mechanism. I revealed the HA concentration in plasma in control rats was much higher 
in the morning than that in the evening that corresponds well with the feeding pattern 
of rats as a nocturnal animal. On the other hand, PAG level was not fluctuated 
compared with HA that suggested the PAG homeostasis is insusceptible to external 
stimulations in normal condition. It is known that both HA and PAG are catabolites of 
essential amino acid phenylalanine. The circadian rhythm of HA is dominantly affected 
by ingestion of phenylalanine as diet whereas PAG is considered to be a metabolite of 
minor metabolic pathway in the body. The phenylalanine catabolism is started from 
deamination by phenylalanine dehydrogenase to form phenylpyruvate. Phenylpyruvate 
metabolism is branched to eventually form phenylacetate and benzoic acid then 
conjugated by glycine to form PAG and HA, respectively. Between these two pathways, 
the conversion to phenylacetate should be the rate limiting step thus the plasma PAG 
level is not affected food consumption. In the other pathway, cinnamic acid that is 
formed by dehydration of phenyllactate is metabolized to benzoic acid via -oxidation. 
The evidence that amiodarone inhibits the mitochondrial -oxidation of fatty acids 
(Fromenty et al., 1990; Fromenty and Pessayre, 1995; Kaufmann et al., 2005; Spaniol et 
al., 2001; Waldhauser et al., 2006) indicates the decrease in HA level in plasma might be 
substituted the molecular mechanism of PLD formation. Further estimation may lead 
that the inhibition of the pathway leading to HA might cause a compensatory increase 
in the alternate metabolic pathway of phenylpyruvate, resulting in the increase in PAG. 
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HA decrease and PAG increase in the urine and plasma could be an index for inhibition 
of -oxidation and they could be a potential surrogate marker for PLD. 
To confirm and verify the utility of the HA and PAG as potential biomarkers, it is 
quite important to setup a quantitative and robust analytical procedure. However, there 
remains several technical issues to investigate absolute concentration of endogenous 
metabolites in biological fluids because there are always existed 'unknown' 
concentration of endogenous components themselves and other analytical coexisting 
substances interfere with metabolite in biological samples to hamper sensitivity and 
selectivity. In Chapter 2, I developed and validated a quantification method by using 
LC/MS/MS procedure for simultaneous quantification of HA and PAG in rat urine. The 
originally constructed post-column infusion procedure successfully evaluated the 
sample-derived analytical interference that the coexisting substances in undiluted 
urine drastically interfered with PAG and HA to hamper their sensitivity and selectivity. 
The calibration curve generated with buffer-based dilution series showed good linearity 
with those from matrix (urine)-based dilution. The robustness and reproducibility were 
also confirmed by intra- and inter-day precision and accuracy tests.  
Currently there has been reported several potential candidates of non-invasive 
biomarkers to monitor DIPL, for example di-22:6-BMP. However, BMP is a lysosomal 
phospholipid which is practically identified to increase in the damaged tissues of 
animals and humans with DIPL and Niemann–Pick type C (NPC) disease. One of the 
advantages for DIPL biomarker to monitor PAG to HA ratio is that both HA and PAG 
are generated from the same precursor phenylalanine so that this indicator is less 
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affected by other external factors. The mechanism and process of drug-induced PLD are 
considered to be complex and might differ from one drug to another; therefore, 
additional studies would be required to confirm the hypothesis with metabolic flux 
analysis using stable isotopes and/or key enzyme inhibitors. Detailed validation, such 
as time-course studies with CADs other than amiodarone and concomitant monitoring 
of histopathological status, would also be required before practical use of the PAG/HA 
ratio as a toxicological index. To apply this hypothesis in the clinic, it should be 
confirmed whether phenylacetylglutamine, an alternate of PAG in humans and 
primates as described above, could be used as an index. Since the PAG/HA ratio in 
plasma showed good correlation with CAD-induced PLD in this study, subsequent 
studies on this biomarker are expected to contribute largely in predicting and 
understanding drug-induced PLD. 
In summary, these novel, non-invasive and highly quantitative biomarkers to monitor 
DIPL status is critically beneficial to avoid drug derived serious toxicity to improve the 
quality of life for patients. 
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